Pfizer
Quarterly Financials
| Values in thousands | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
|---|---|---|---|---|
Revenue | $16,583,000 | $15,034,000 | $14,450,000 | $17,557,000 |
Gross Profit | 12,555,000 | 10,942,000 | 10,902,000 | 12,285,000 |
EBITDA | 5,624,000 | 1,636,000 | 5,451,000 | 756,000 |
EBIT | 4,047,000 | 14,000 | 3,838,000 | -931,000 |
Net Income | 3,242,000 | -248,000 | 2,687,000 | -1,648,000 |
Net Change In Cash | 16,583,000 | 15,034,000 | 14,450,000 | 17,557,000 |
Free Cash Flow | 4,802,000 | 302,000 | 2,179,000 | 4,504,000 |
Cash | 1,824,000 | 976,000 | 1,703,000 | 1,142,000 |
Basic Shares | 5,751,000 | 5,699,000 | 5,731,000 | 5,686,000 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $62,579,000 | $63,627,000 | $59,554,000 | $101,175,000 |
Gross Profit | 46,512,000 | 45,776,000 | 34,600,000 | 66,831,000 |
EBITDA | 16,783,000 | 18,127,000 | 9,557,000 | 41,031,000 |
EBIT | 10,191,000 | 11,114,000 | 3,267,000 | 35,967,000 |
Net Income | 7,771,000 | 8,031,000 | 2,119,000 | 31,372,000 |
Net Change In Cash | 62,579,000 | 63,627,000 | 59,554,000 | 101,175,000 |
Cost of Revenue | -1,350,000 | |||
Free Cash Flow | 9,076,000 | 9,835,000 | 4,793,000 | 26,031,000 |
Cash | 1,142,000 | 1,043,000 | 2,853,000 | 416,000 |
Basic Shares | 5,686,000 | 5,700,000 | 5,709,000 | 5,733,000 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-09-30 | $0.87 |
2026-06-30 | $0.77 |
2026-03-31 | $0.75 |
2025-12-31 | $0.66 |